AbbVie Inc. $ABBV Stock Sold by Lynch Investment Planning LLC

Lynch Investment Planning LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 53.5% during the third quarter, Holdings Channel reports. The institutional investor owned 1,701 shares of the company’s stock after selling 1,958 shares during the quarter. Lynch Investment Planning LLC’s holdings in AbbVie were worth $445,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ABBV. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC raised its holdings in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after acquiring an additional 48 shares during the period. IMG Wealth Management Inc. lifted its position in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after acquiring an additional 153 shares in the last quarter. Principia Wealth Advisory LLC lifted its position in shares of AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Tacita Capital Inc bought a new position in shares of AbbVie in the second quarter worth $42,000. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a biologics license application to the FDA for etentamig, a next-generation BCMA×CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, the treatment significantly improved overall response rate and progression-free survival versus available standard therapies, supporting potential pipeline diversification beyond immunology. AbbVie Submits BLA for Etentamig
• Positive Sentiment: The FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease, including an on-body injector that enables an at-home treatment start. The approval could improve patient convenience and help support continued growth of AbbVie’s key immunology franchise. FDA Approves SKYRIZI Crohn’s Disease Regimen
• Positive Sentiment: Goldman Sachs raised its AbbVie price target to $294, while reports that Citadel has built an approximately $900 million position may reinforce institutional confidence. Analysts also identify SKYRIZI and RINVOQ as important growth drivers.
• Neutral Sentiment: Options markets imply an approximately 5% potential move around the October 30 earnings release. AbbVie previously exceeded quarterly EPS and revenue expectations, but investors will focus on SKYRIZI and RINVOQ sales, expenses and updated guidance.
• Negative Sentiment: Some analysts view ABBV as fully valued after its strong run, with rising expenses, declining estimates and intensifying competition creating near-term risks. Erste Group Bank also reduced its EPS forecast, potentially limiting upside ahead of earnings.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Down 0.0%

Shares of ABBV opened at $286.70 on Wednesday. The firm’s 50 day simple moving average is $267.66 and its 200 day simple moving average is $236.20. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent research reports. UBS Group increased their price objective on AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a report on Tuesday, October 6th. Cantor Fitzgerald raised their price target on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. The Goldman Sachs Group raised their price target on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a report on Friday. HSBC boosted their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company upped their price target on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.